Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness.

This study found only limited benefit for amisulpride augmentation of clozapine in schizophrenia that had shown an insufficient response to a trial of clozapine monotherapy. However, amisulpride augmentation has the potential to be cost-effective in the short term and possibly the longer term. The design of future trials of such a treatment strategy should take into account that a clinical response may not be evident within the 4–6 week follow-up period usually considered adequate in studies of antipsychotic treatment of acute psychotic episodes and also the need for adequate assessment of adverse effects, including cardiac side effects.

http://ift.tt/2wNACWJ